ClinicalTrials.gg
CompletedNCT03790332Updated Oct 21, 2025

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

A Phase 1/2 interventional study of Ibrutinib in Chronic Graft Versus Host Disease, sponsored by Pharmacyclics LLC.. Completed at 48 sites in 13 countries. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2025-10-21.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
1 Year to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome — none open to participants now, 1 under way, 1 of them phase 3. ibrutinib · Bronchiolitis Obliterans Syndrome.

Enrollment
4th of 11
59 · median 19
Started
2018
the only one that year
Phase 1/2
3 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
4 of 11
Pharmacyclics LLC.

Among the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome, this one is the 4th largest by enrollment, is the only one that started in 2018, is one of 3 in phase 1/2, and was the 7th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

None of the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome is open now. The open studies under Bronchiolitis Obliterans Syndrome, anywhere →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 1 Year to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing ibrutinib in Bronchiolitis Obliterans Syndrome as a file.
02

Study summary

Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)

03

Conditions studied

  • Chronic Graft Versus Host Disease

Keywords

  • cGVHD
  • chronic graft versus host disease
  • PCYC1146IM
  • Pediatric
  • GVHD
  • chronic
  • 1146
  • Pharmacyclics
  • PCYC
  • Imbruvica
  • Ibrutinib
  • Immunology
  • graft versus host disease
  • corticosteroids
  • prednisone
  • PCI32765
  • PCYC1146
  • refractory
  • new onset graft versus host disease
  • refractory graft versus host disease
  • moderate cGVHD
  • severe cGVHD
  • moderate chronic graft versus host disease
  • severe chronic graft versus host disease
04

Who can participate

Ages eligible
1 Year to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Key Eligibility:

Inclusion criteria

Inclusion Criteria:

  1. Part A: Subjects with moderate or severe cGVHD after failure of 1 or more
  2. Part B: Subjects with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy, or subjects with new onset moderate or severe cGVHD and in need of systemic
  3. History of stem cell transplantation
  4. Age

    • Part A: ≥1 to \<12 years of age at the time of enrollment
    • Part B: ≥1 to \<22 years of age at the time of enrollment
  5. or Lansky (subjects \<16 years of age) performance status ≥60

Key Eligibility:

Exclusion criteria

Exclusion Criteria:

  1. Presence of single organ genito-urinary involvement as the only manifestation of cGVHD
  2. Received an agent within 28 days before enrollment.
  3. Received donor lymphocyte infusion (DLI) within 56 days before enrollment
  4. Progressive underlying malignant disease or active post-transplant lymphoproliferative disease
  5. Any uncontrolled infection or active infection requiring ongoing systemic treatment
  6. Known bleeding disorders
  7. Active virus (HCV) or virus (HBV)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Phase 1/2

    Part A: Subjects ≥1 to \<12 years of age with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy, will receive oral ibrutinib once daily to determine Recommended Pediatric Equivalent Dose (RPED). Part A Continuation: Subjects participating in Part A may continue receiving daily ibrutinib until the RPED is determined, at which time their dose may be adjusted to the RPED. Part B: Subjects ≥1 to \<12 years of age( upper age limit is \< 22 years) with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy or with newly diagnosed moderate or severe cGVHD will be dosed at the RPED. Subjects ≥12 will be given 420mg orally ibrutinib once daily.

    Drug: Ibrutinib

Interventions

  • Ibrutinib capsule, tablet, or suspension administered orally once daily

    Also known as: IMBRUVICA®, PCI-32765

06

What researchers measure

Primary outcomes

  1. Part A- PK (measured by AUC) will be reported descriptively

    Time frame: Approximately 24 months

  2. Part B- PK (measured by AUC) will be reported descriptively

    Time frame: Approximately 7 years

  3. Number of patients with adverse events as a measure of safety and tolerability

    Time frame: Approximately 7 years

Secondary outcomes

  1. Part A- Number of patients with adverse events as a measure of safety and tolerability

    Time frame: Approximately 24 months

  2. Part A- Pharmacodynamic effects as measured by in vitro BTK occupancy will be reported descriptively

    Time frame: Approximately 24 months

  3. Part A continuation cohort and Part B-Response rate at 24 weeks

    Time frame: Approximately 6 months after last subject in enrolled

  4. Part A continuation cohort and Part B- Duration of response (DOR)

    Time frame: Up to 48 weeks

  5. Part A continuation cohort and Part B-Overall survival (OS)

    Time frame: Approximately 5 years after last subject enrolled

  6. Part A continuation cohort and Part B-Late Effects Surveillance

    Time frame: Up to 5 years post enrollment

  7. Growth Parameter height in meters will be reported descriptively

    Subjects will be monitored for growth and development

    Time frame: Up to 5 years post enrollment

  8. Growth Parameter weight in kilograms will be reported descriptively.

    Subjects will be monitored for growth and development

    Time frame: Up to 5 years post enrollment

  9. Available immune reconstitution laboratory parameters will be reported descriptively

    Subjects will be monitored for immune reconstitution

    Time frame: Up to 5 years post enrollment

  10. Late effects (Adverse events suspected to be related to treatment) will be quantified and reported descriptively

    Time frame: Up to 5 years post enrollment

07

Study locations

48 sites
  • City of Hope
    Duarte, California 91010, United States
  • Rady Children's Hospital
    San Diego, California 92123, United States
  • University of California
    San Francisco, California 94158, United States
  • Children's Hospital
    Aurora, Colorado 80045, United States
  • Children's National Medical Center
    Washington D.C., District of Columbia 20010, United States
  • Johns Hopkins All Children's Hospital
    St. Petersburg, Florida 33701, United States
  • Ann & Robert H Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Minnesota Masonic Children's Hospital
    Minneapolis, Minnesota 55454, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105-2729, United States
  • Primary Children's Hospital
    Salt Lake City, Utah 84113, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Cancer Center for Children. The Children's Hospital at Westmead
    Westmead, New South Wales 2145, Australia
  • Queensland Children's Hospital
    South Brisbane, Queensland 4101, Australia
  • The Royal Children's Hospital
    Parkville, Victoria 3052, Australia
  • Sydney Children's Hospital
    Randwick, 2031, Australia
  • St. Anna Kinderspital
    Vienna, 1090, Austria
  • children's and Women's Health Centre of British Columbia
    Vancouver, British Columbia V6H 3V4, Canada
  • CHU Sainte-Justine
    Montreal, Quebec H3T1C5, Canada
  • CHU Nantes - Hopital Enfant Adolescent
    Nantes, 44093, France
  • Hôpital Robert-Debré Ap-Hp
    Paris, 75019, France
  • Charite-Universitaetsmedizin Berlin
    Berlin, 13353, Germany
  • Hadassah Medical Centre
    Jerusalem, 9112001, Israel
  • Schneider Children's Medical Center in Israel
    Petah Tikva, 4920235, Israel
  • The Edmond and Lily Safra Children's Hospital
    Ramat Gan, 5262100, Israel
  • U.O.C. Ematologia Oncoematologia Pediatrica
    Pavia, PV 27100, Italy
  • Fondazione MBBM-Clinica Pediatrica
    Monza, 20900, Italy
  • Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica
    Roma, 00165, Italy
  • S.C. Farmacia Pediatrica - Presidio Ospedaliero Infantile Regina Margherita
    Turin, 10126, Italy
  • Princess Maxima Center
    Utrecht, 3584 CS, Netherlands
  • Federal State Budgetary Institution "Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
    Moscow, 117997, Russia
  • Federal State Budgetary Educational Institution of Higher Professional Education "LP.Pavlov First Saint Petersburg State Medical
    Saint Petersburg, 197022, Russia
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Seoul Saint Mary's Hospital
    Seoul, 06591, South Korea
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Infantil Universitario Nino Jesus
    Madrid, 28009, Spain
  • Hospital Universitario Universitario La Paz
    Madrid, 28046, Spain
  • Safari Day Care, Great Ormond Street Hospital
    London, Greater London WC1N 3JH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Oct 2025, 82 months.

Of 24 phase 1/2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 87. This study's 82 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2018
First posted
Dec 31, 2018
StartActual
Nov 19, 2018
Primary completionActual
Oct 9, 2025
CompletionActual
Oct 9, 2025
Last update
Oct 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03790332
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Dec 31, 2018
Start date
Nov 19, 2018
Primary completion
Oct 9, 2025
Completion
Oct 9, 2025
Last update
Oct 21, 2025

Study contacts

Gauri Sunkersett
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion